ILC in chronic inflammation, cancer and targeting with biologicals

Mol Aspects Med. 2021 Aug:80:100963. doi: 10.1016/j.mam.2021.100963. Epub 2021 Mar 14.

Abstract

Since their discovery, Innate Lymphoid Cells (ILC) have emerged as important effector cells, serving multiple roles in maintaining tissue homeostasis and responding to tissue insults. As such, dysregulations of their function and distribution have been observed in a variety of immune-mediated diseases, suggesting a specific role for ILC in the pathophysiology of several disorders including chronic inflammation and cancer. Here, we provide an updated view on ILC biology dissecting their pathological or protective contribution in chronic inflammatory diseases such as multiple sclerosis, inflammatory bowel diseases, psoriasis, rheumatoid arthritis, asthma and COPD, atherosclerosis, also exploring ILC role in tumor surveillance and progression. Throughout the review, we will also highlight how the potential dual role of these cells for protective or pathogenic immunity in many inflammatory diseases makes them interesting targets for the development of novel therapeutic strategies, particularly promising.

Keywords: Autoimmunee disease; Biological therapeutics; Cancer; Chronic inflammation; Innate lymphoid cells; Tertiary lymphoid structures.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products*
  • Humans
  • Immunity, Innate
  • Inflammation / drug therapy
  • Lymphocytes
  • Neoplasms* / drug therapy

Substances

  • Biological Products